SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2017 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (277)12/15/2017 10:17:41 PM
From: BulbaMan  Read Replies (1) of 344
 
12/15/2017 Contest update
A few popular portfolio picks appeared to suffer burn-out following the ASH conference and the Contest median had a rough week.
At Friday’s close, the Contest median was up 39.98% YTD (vs. up 45.47% a week ago), the Nasdaq Biotech Index (NBI) was up 20.70% YTD (vs. up 20.41% a week ago) and the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI), was up 38.37% YTD (vs. up 42.03% a week ago). The Nasdaq Composite Index (NCI) closed up 28.86% YTD (vs. up 27.07% a week ago).
It’s down to the wire for the Contest Crown! Taking first place is KMASTR’s portfolio, up 125.52% YTD, just a nick ahead of second place IMAN’s portfolio, up 125.12% YTD. Moving into third place is GHMM’s portfolio, up 107.45% YTD.
At Friday's close, 45 of the 48 Contest portfolios were still in the green, with 36 beating the NBI and 26 beating the SPSIBI.
The 195 Contest portfolio stock picks have an average YTD gain of 32.95% and a median YTD gain of 5.95%, with 104 of the 195 picks up for the year.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.)
Portfolio adjustments: To my great dismay, the OCRX buyout closed before the end of the year. Nine Contest portfolios hold OCRX with four of these having a prior buyout, so doing the multiple reallocations was a pain. A further complication was that the OCRX buyout involved a CVR. Since the CVR isn’t traded, I assumed all the OCRX holders sold their shares at $1.79, the closing price on its final trading day, 12/8/17. I then reallocated the cash to the remaining shares in each portfolio using Friday’s close.
(All corrections, especially adjustments for splits, greatly appreciated.)
Happy Chanukah!
Enjoy a relaxing weekend biotechies!
Peace & good health,
Bulba

			12/15/17	
Rank Name Profit/Loss
1 KMASTR 125,516
2 IMAN 125,120
3 GHMM 107,445
4 ROBO 102,402
5 NIGEL 94,560
6 AJM 90,051
7 BIOMAV 89,381
8 SCARAM 88,972
9 SMALLB 86,611
10 HRS 83,702

Week's Top 5 Gainers
Symbol 12/8/17 12/15/17 Wk.%chg.
PTI 2.41 4.99 107.05%
ARGX 30.45 58.21 91.17%
ZSAN 0.58 0.71 22.40%
GHDX 30.01 35.55 18.46%
OCUL 4.15 4.84 16.63%

Week's Worst 5 Losers
Symbol 12/8/17 12/15/17 Wk.%chg.
AFMD 1.95 1.25 -35.90%
TRIL 11.25 7.55 -32.89%
SYRS 12.370 8.990 -27.32%
PPHM 5.26 3.86 -26.62%
JUNO 58.65 44.68 -23.82%
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext